Ascension Via Christi Home Medical Durable Medical Equipment & Medical Supplies Location: 2601 Central, Dodge City, Kansas 67801 Phone: (620) 227-7080 |
Walmart Pharmacy 10-0372 Durable Medical Equipment & Medical Supplies Location: 1905 N 14th Ave, Dodge City, Kansas 67801 Phone: (620) 225-0872 |
Walgreens #7817 Durable Medical Equipment & Medical Supplies Location: 1801 N 14th Ave, Dodge City, Kansas 67801 Phone: (620) 225-6095 |
Dillon's Pharmacy #001 Durable Medical Equipment & Medical Supplies Location: 1700 N 14th Ave, Dodge City, Kansas 67801 Phone: (303) 571-1943 |
Gibson's Pharmacy Of Dodge City Long Term Care Pharmacy Location: 2401 Central Ave, Dodge City, Kansas 67801 Phone: (620) 227-8193 |
Phillips Chiropractic And Physical Medicare Supplier Location: 2200 Summerlon Cir, Dodge City, Kansas 67801 Phone: (620) 225-4139 |
Life In Motion Orthotic & Prostheti Prosthetic/Orthotic Supplier Location: 2601 Central Ave, Dodge City, Kansas 67801 Phone: (620) 225-0113 |
Richard L Roenfeldt Od Medicare Supplier Location: 2020 1st Ave, Dodge City, Kansas 67801 Phone: (620) 225-0225 |
Vierthaler Kessen Optometry Medicare Supplier Location: 208 W Ross Blvd, Dodge City, Kansas 67801 Phone: (620) 225-6500 |
Idocs Of Dodge City Medicare Supplier Location: 2520 N 14th Ave, Dodge City, Kansas 67801 Phone: (620) 227-3071 |
News Archive
This week, the U.S. Food and Drug Administration launched Innovative Science and Technology Approaches for New Drugs (ISTAND), a pilot program that will help reduce and replace animal testing as part of drug development.
Elsevier, the world-leading publisher of scientific, technical and medical information products and services, proudly announces the release of a brand-new single volume comprehensive book on reconstructive techniques for degenerative mitral valve disease by the internationally renowned cardiac surgeon and educator, Dr. Alain Carpentier. The book will launch at the 90th Annual Meeting of the American Association for Thoracic Surgery at the Metro Toronto Convention Centre in Toronto, Ontario, Canada, May 1 - 5, 2010.
ChromaDex Corporation, a leader in phytochemical reference standards and contract research, today announced financial results for the second quarter of 2010. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (U.S. GAAP), ChromaDex announced a net loss attributable to common stockholders of $0.01 per share for the thirteen week period ended July 3, 2010.
An HIV vaccine candidate trialed in Sub-Saharan Africa offers no substantial protection against HIV infection among young women, the study organizers say.
› Verified 5 days ago